Business
DECN Accepts 4th Unsolicited Proposition for its GenUltimate TGB Product, and Today Launches its GenUltimate TGB Product into Select International Markets
DECN Accepts 4th Unsolicited Proposition for its GenUltimate TGB Product, and Today Launches its GenUltimate TGB Product into Select International Markets.
About this update from Decision Diagnostics Corp
[{"type":"text","content":"DECN Awaits Major Proposition On Or About June 10, Notifies Two Entities That Their Earlier Propositions Do Not Meet Requirements, Does Not Request Counter-Proposals LOS ANGELES, CA / ACCESSWIRE / June 6, 2019 / Decision Diagnostics Corp. (OTC PINK: DECN) is a 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! ("Sunshine") diabetes test strip, the internationally launched GenSure! ("Feather") diabetes test strip, and its GenChoice! ("Ladybug") test strip now under review for FDA 510K clearance. The company also markets the PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system, and the GenUltimate! Test 4Pets test strip and Avantage! meter launched earlier in 2019, and the panacea GenUltimate! TBG ("Dragonfly") highly precise and outre' accurate diabetes testing system, launched today June 6, 2019, in select off-shore markets. Keith Berman, CEO of DECN commented on today's news, "Over the weekend we received a fourth unsolicited proposition for a strategic transaction involving our GenUltimate! TBG system. This fourth proposition, in some ways the richest received thus far, came unexpectedly from an entity that at first study cannot make full use of our technology in their current business. We will inquire about this issue in the coming days. We also await a solicited proposition, graciously agreed to by an International entity, and due on or about June 10." The company reminds shareholders, interested parties and investors that often other companies forward offers or proposals, or perhaps describe partnerships, and even might threaten a target company such as DECN, for their own accounts. To that end, the company has turned down two earlier propositions from larger entities and has not requested counter proposals. Propositions that passed the company's initial reviews fall into a certain transaction category, as will the solicited proposition due on or about June 10.Mr. Berman continued, "Today we launch our GenUltimate TBG system into select markets in the Middle East, portions of Sou...